Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

News Release

Salignostics Advances Saliva-Based HIV Testing with Successful Clinical Trial in Ethiopia

Salignostics

Salignostics, a leader in saliva-based diagnostic innovation, proudly announces the successful completion of a clinical trial in Ethiopia for its groundbreaking saliva-based HIV rapid test. This major milestone brings Salignostics closer to providing a transformative solution for HIV testing, particularly in areas with limited access to healthcare infrastructure. The trial, conducted in November 2024, evaluated 50 saliva samples from individuals diagnosed with HIV alongside 50 samples from healthy participants. The results demonstrated exceptional accuracy, with sensitivity exceeding 90% and specificity surpassing 98%. These findings underscore the reliability of saliva as a diagnostic medium and highlight its potential to address critical healthcare challenges worldwide. Accurate, accessible HIV testing is vital for early detection and treatment, especially in underserved regions. Salignostics’ saliva-based test eliminates the need for blood draws and specialized equipment, offering a cost-effective and non-invasive alternative that can be deployed in homes, clinics, or community health settings. This innovation not only reduces barriers to testing but also empowers individuals to take control of their health with privacy and convenience. “This successful trial highlights the value of saliva as a diagnostic medium,” said Dr. Guy Krief, Co-founder and Deputy CEO of Salignostics. “By leveraging our technology, we aim to complement existing HIV testing methods and provide a reliable, accessible solution that meets the needs of diverse communities worldwide.” The global HIV diagnostics market is rapidly expanding, driven by increasing demand for decentralized and user-friendly solutions. The market is projected to reach $3.88 billion by 2021, with forecasts of further growth to over $7 billion by 2034 at a compound annual growth rate (CAGR) of 7.5% from 2024 to 2034. Building on its success with saliva-based diagnostics, Salignostics continues to expand its portfolio. The company has a proven track record, including CE, UKCA, and TGA certifications for its Salistick pregnancy test, which has achieved over 500,000 units sold and ordered across markets such as the UK and Israel. Salignostics’ development pipeline also includes applications for oral cancer, respiratory conditions, and sexually transmitted infections, further demonstrating the versatility of saliva as a diagnostic tool. For Salignostics, the successful Ethiopian trial is a significant step forward in transforming global healthcare. By providing accurate and accessible HIV testing, the company is addressing critical gaps in public health while reinforcing its commitment to innovation and quality in diagnostics. About Salignostics Founded in 2017 in Jerusalem, Salignostics is a global leader in saliva-based diagnostics. The company’s proprietary technology has been successfully commercialized, with its Salistick pregnancy test achieving over 500,000 units sold and ordered in markets such as the UK and Israel. Now approved by CE, UKCA, and TGA, Salignostics is actively expanding its portfolio of innovative, user-friendly diagnostic solutions. For more information about Salignostics and its groundbreaking saliva-based diagnostics, visit www.salignostics.com Founded in 2017 in Jerusalem, Salignostics is a global leader in saliva-based diagnostics. The company's proprietary technology has been successfully commercialized, with its Salistick pregnancy test achieving over 500,000 units sold and ordered in markets such as the UK and Israel. Now approved by CE, UKCA, and TGA, Salignostics is actively expanding its portfolio of innovative, user-friendly diagnostic solutions. For more information about Salignostics and its groundbreaking saliva-based diagnostics, visit www.salignostics.com Contact Details Salignostics Guy Krief | Co-founder and Deputy CEO, Salignostics guykrief@salignostics.com Company Website https://www.salignostics.com/

January 21, 2025 05:15 PM Eastern Standard Time

Flash Earns HITRUST Certification, a First in Parking Technology

Flash

Flash, the leading AI-powered parking technology provider, today announced it has achieved HITRUST Certification for its PARCS and Valet solutions, the first and only parking technology provider to earn the distinction. The achievement confirms Flash’s data security practices meet the highest standards trusted by 81 percent of U.S. hospitals and health systems. Flash's HITRUST-certified PARCS and Valet solutions align its security frameworks with those of its healthcare clients and reduce their implementation complexity and risk. The certification also gives assurance to patients, visitors, physicians and staff that their information is safe from the moment they enter the parking facility. “We have a track record of setting new standards in parking," said Flash CEO Dan Sharplin. “Our focus on reimagining the parking experience calls for putting security front and center, within and beyond healthcare. We’re also committed to a great experience for operators and owners, and this certification allows us to carry the technical burden of compliance on their behalf.” Flash PARCS and Valet solutions have earned the trust of the country’s largest medical district and from healthcare systems in major metros nationwide, including Atlanta, Boston, Chicago, Denver, Houston, New York City, Orange County, Phoenix, Pittsburgh and San Diego. Flash’s industry-leading parking technology has also earned designation as a Level 1 Service Provider by the Payment Card Industry (PCI) Data Security Standards (DSS), which it has maintained for 11 consecutive years. Its cloud-based platform can process over 500 million transactions yearly in a secure environment that limits the risk of data loss, disruption, or corruption. Operating entirely in the cloud also allows Flash to manage compliance for operators and owners, pushing security updates and routine system checks required by PCI and HITRUST standards over the air, which become operational within minutes. About Flash Flash is a pioneering technology company bringing seamless parking and EV charging experiences to drivers through a first-of-its-kind digital ecosystem. Flash’s platform connects reservable parking and charging in the apps drivers use daily with garage, surface lot, event, and valet parking locations—connected and controlled via a cloud-based operating system with unrivaled intelligence. Customer-obsessed brands partner with Flash to deliver digital, easy-to-use, reliable, and increasingly frictionless experiences to drivers eager to pay for a solution that eliminates wasted time, excess emissions, and stress. The solution has arrived. Visit www.flashparking.com to learn more. Contact Details Ray Young +1 512-694-6097 ray@razorsharppr.com Company Website https://www.flashparking.com/

January 21, 2025 10:00 AM Central Standard Time

Soligenix Targets Psoriasis With New Therapy

Benzinga

By Kyle Anthony, Benzinga The skin is the largest organ in the human body. Its softness allows for movement and flexibility, yet it is also durable enough to typically resist breaking or tearing. As one of the body’s more versatile organs, it serves multiple functions, such as being the first line of defense against bacteria and other organisms. However, the skin has another vital role as an indicator of good health; if someone is sick, it often shows in their skin. Soligenix, Inc. (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases and areas of unmet medical need, is utilizing its pharmaceutical expertise to tackle psoriasis, an autoimmune skin condition that causes itchiness and discomfort. Psoriasis Explained Psoriasis is an autoimmune condition that causes skin inflammation, exacerbated by T-cells of the adaptive immune system (autoimmune response). Symptoms include thick areas of discolored skin covered with scales called plaques. Psoriasis is a chronic skin condition that can flare up unexpectedly. Presently, there is no cure for this condition. According to the National Psoriasis Foundation, approximately 125 million people worldwide suffer from this condition, with more than 8 million of them being in the U.S. Psoriasis has several types, each manifesting on the body and affecting individuals differently. Plaque psoriasis is the most common type; about 80% to 90% of people with psoriasis have plaque psoriasis. Most psoriasis patients have mild or moderate forms of the disease. The former means less than 3% of the body surface area is involved, while the latter usually involves between 3% and 10%. Disease involving more than 10% of body surface area is generally classified as severe. The implications of having psoriasis are not purely aesthetic, as it can decrease a patient’s quality of life including itchiness, dry, cracked skin that can be susceptible to infection and potentially anxiety relating to appearance. Psoriasis can also be associated with cardiovascular, arthritic and metabolic diseases, as well as anxiety, depression and suicide. Psoriasis itself can evolve into chronic inflammatory arthritis called psoriatic arthritis. In addition, individuals with severe psoriasis can have an increased risk of lymphoma, like cutaneous T-cell lymphoma. Soligenix’s Treatment Of Psoriasis Generally, treatment for psoriasis is predicated on its severity. The primary objective in treating psoriasis is to reduce the rate at which skin cells grow and divide and to remove the scales. Treatments can be divided into topical treatments, light therapy (phototherapy or photodynamic therapy) and systemic (oral or injected) medications. Soligenix’s product offering for treating psoriasis is SGX302. This treatment utilizes photodynamic light therapy and synthetic hypericin to treat mild-to-moderate psoriasis. Hypericin is renowned for its antimicrobial properties, including activity against bacteria, fungi and viruses. SGX302’s treatment methodology involves applying an ointment to the affected areas and utilizing a visible light to activate it. Soligenix reports that synthetic hypericin tends to accumulate in T-cells. When synthetic hypericin is activated, it creates oxygen radicals, which subsequently kill the targeted T-cells, Soligenix says. Soligenix reports that clinical studies with SGX302 have found it safe and efficacious in treating the disease. The press release regarding the phase 2a study noted that all patients tolerated SGX302 therapy well, and no drug-related adverse events were identified. Furthermore, the Psoriasis Activity and Severity Index (PASI) score, another well-characterized measure of treatment success, had a mean drop of approximately 50% over the 18-week treatment for patients in cohort 2. Regarding the success of their clinical studies and the learnings gathered, Christopher J. Schaber, PhD, president and CEO of Soligenix, has stated, "We are pleased with the preliminary findings from our ongoing Phase 2a trial. Current estimates show as many as 60-125 million people worldwide living with the condition, with a global treatment market valued at approximately $15 billion in 2020 and projected to reach as much as $40 billion by 2027. The success of HyBryte™ in targeting malignant T-cells during CTCL clinical trials is a promising indicator of the ability of SGX302 to provide a much-needed approach for the treatment of mild-to-moderate psoriasis, also caused by dysregulated T-cells." Soligenix says it is making material and meaningful progress in treating psoriasis. As the firm progresses in tackling psoriasis and other rare diseases, it hopes to establish a distinct value proposition in the market. For more information on Soligenix's recent stock performance, click here. Featured photo by Louis Reed on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

January 17, 2025 08:30 AM Eastern Standard Time

Image

U.S. surpassed 48,000 organ transplants in 2024

United Network for Organ Sharing

Today, the United Network for Organ Sharing (UNOS) announced that 48,149 organ transplants were performed in 2024, according to data from the Organ Procurement and Transplantation Network (OPTN). This is the first time the United States has ever performed more than 48,000 organ transplants in one year and represents a critical step in the nationwide effort to increase the number of lifesaving organ transplants while improving the system. On average, the U.S. performed 132 transplants a day in 2024. This lifesaving work was made possible thanks to the selfless gifts of life provided by 16,988 deceased donors and 7,030 living donors, as well as the support provided by so many donor families and the expertise of medical professionals across the country. “Each transplant represents an individual, a family, a story, and a life saved or improved,” said UNOS CEO Maureen McBride, Ph.D. “Each transplant also represents a selfless decision made by a grieving family or an inspired living donor, and it is incumbent upon us to honor each and every one of those irreplaceable gifts. That means working together to enact substantive reforms that increase the total number of transplants and the number of recovered donor organs ultimately transplanted.” UNOS continues to engage with Congress and other stakeholders and advocate for pragmatic policy changes that would benefit patients in need of transplants, which McBride outlined in a letter sent to the House Energy and Commerce Committee in December 2024 and was signed by nearly 70 donation and transplant professionals. These proposals, which require Congressional action, include: Mandating automated donor referrals to improve information sharing and ensure organ procurement organizations are alerted to every potential organ donor quickly and efficiently. Mandating in-cabin airline transportation for organs to drastically reduce the likelihood that lifesaving organs are damaged, lost or delayed in transit. Implementing a national, centralized, system-wide tracking system for unaccompanied organs to reduce delays, provide surgical teams with critical travel information, and produce data to drive additional improvements. Incentivizing transplant hospitals to accept harder-to-place organs by compensating them at a higher rate through Medicare when they transplant more medically complex kidneys. The data suggests this change could prevent an estimated 4,000 deaths. Taken together, this slate of reforms advanced by UNOS could result in a marked increase in both donor referrals and organ donors, a reduction in the number of organs that are not ultimately transplanted, and even more patients receiving the gift of life. “We are humbled that our community’s efforts and the generosity of so many across the country has resulted in over 48,000 transplants in a single year, but there is more work to do, and we cannot be satisfied with the status quo,” McBride said. “We will continue our work to strengthen the system as long as there are patients waiting for a transplant.” To learn more about UNOS’ recommendations, see UNOS’ Action Agenda. About UNOS The United Network for Organ Sharing (UNOS) is a nonprofit organization that serves the organ donation and transplant system and broader public health community through its work developing new technologies and initiatives, conducting data-driven research and analysis, providing expert consulting services, advocating for patients, and being a leader in bringing communities together to save lives. Contact Details United Network for Organ Sharing Anne Paschke anne.paschke@unos.org Company Website https://unos.org

January 15, 2025 12:41 PM Eastern Standard Time

Image

Forum Health Expands Its Footprint in the DC Metro with a New Integrative Health Clinic Offering Personalized Care

Forum Health

Forum Health, LLC, a nationwide leader in functional and integrative medicine, is excited to announce the opening of its newest clinic in Silver Spring, Maryland. The new location will deliver the same high-quality, patient-centered care that has become synonymous with Forum Health, offering a comprehensive suite of services. Learn more about Forum Health Silver Spring. Phil Hagerman, CEO: “We are thrilled to bring our innovative functional medicine approach to the vibrant Washington, DC suburb of Silver Spring. At Forum Health, we believe in treating the whole person through personalized care and cutting-edge testing and therapies. This new clinic expands our ability to deliver transformative health outcomes to more patients.” Leading the clinic is Dr. Lynese Lawson, renowned functional medicine physician board-certified in anti-aging and regenerative medicine, and Dr. Umza Mian, board-certified physician in Anti-Aging and Regenerative Medicine (A4M). Joining the team is Jared Sharp, NP, an experienced practitioner specializing in plasma therapy, advanced biologics, regenerative therapies, and functional medicine, with five years in primary care and orthopedics. Designed to empower patients to take control of their health through personalized, data-driven treatment plans, Forum Health Silver Spring provides advanced diagnostics, cutting-edge therapies, and integrative solutions to address a wide range of health concerns, including: - Hormonal and Thyroid Health Optimization: Restoring balance through bioidentical hormone replacement therapy and tailored wellness strategies. - Advanced Wellness Strategies: Using cutting-edge treatments to provide maximum success for patients who desire to optimize every aspect of their health. - Cognitive Decline and Alzheimer’s Disease: Comprehensive plans to improve brain health and prevent and reverse cognitive decline using the Bredesen Protocol. - Weight Loss and Metabolic Health: Scientifically backed programs to support sustainable weight loss and improve overall metabolic function. - Chronic Disease Management: Addressing the root causes of complex and undiagnosed conditions to restore vitality such as Lyme disease and mold toxicity. To further enhance care offerings, the clinic is introducing musculoskeletal shockwave therapy, a revolutionary treatment for musculoskeletal pain, designed to stimulate healing and restore mobility, addressing a variety of conditions such as chronic pain, tendonitis, and injuries. To further enhance care offerings, the clinic is introducing multiple regenerative therapies including plasma therapy, advanced biologics, and low intensity shockwave therapy - a pioneering treatment for musculoskeletal pain, designed to stimulate healing and restore mobility, addressing a variety of conditions such as chronic pain, tendonitis, and injuries. Lynese Lawson, DO, ABAARM, IFMCP: “We’re thrilled to bring Forum Health’s transformative wellness approach to Silver Spring and the greater Maryland/D.C. metro. Our focus on personalized care and addressing the root causes of health concerns will empower patients in this community to take charge of their health and achieve lasting well-being.” The Silver Spring clinic will also feature a highly skilled team of medical professionals who blend conventional medicine with natural remedies, lifestyle interventions, and advanced technology. Patients will benefit from a warm, collaborative environment that prioritizes long-term health and wellness. Grand Opening and Appointment Scheduling The Forum Health Silver Spring clinic opened its doors in early December 2024. Appointments can be scheduled here or by calling 703-822-5003. About Forum Health, LLC Forum Health, LLC is a nationwide provider of personalized healthcare steeped in the powerful principles of functional and integrative medicine. Our providers take a root-cause approach to care exploring lifestyle, environment, and genetics to help each patient achieve their ultimate health goals. Members have access to advanced medical treatments and technology, with care plans informed by data analytics and collaborative relationships. For more, visit www.forumhealth.com. integrative Contact Details Britt Wittelsberger +1 410-852-0738 bwittelsberger@forumhealth.com Company Website https://forumhealth.com

January 14, 2025 08:50 AM Eastern Standard Time

CURE ALZHEIMER’S FUND NAMES SIX NEW MEMBERS TO ITS RESEARCH LEADERSHIP GROUP

Alzheimer’s Disease Research Foundation

Cure Alzheimer’s Fund announced today that six scientists specializing in Alzheimer’s disease and related research have joined its Research Leadership Group (RLG). The expertise and active engagement of the RLG guide Cure Alzheimer’s Fund to support research with the highest probability of preventing, slowing or reversing Alzheimer’s disease. RLG members provide vital insights into emerging and innovative scientific ideas from labs around the world and are a main source of referrals to promising researchers and their work. Additionally, the RLG plays a crucial role in shaping the nonprofit’s grant portfolio strategy by providing critical feedback and recommendations. Since its inception in 2004, Cure Alzheimer’s Fund has distributed more than $219 million in grants. “Our Research Leadership Group and their collective scientific expertise and knowledge are tremendous assets to our organization,” said Meg Smith, CEO of Cure Alzheimer’s Fund. “Their counsel ensures we fund the most promising avenues of research that will advance our understanding of Alzheimer’s disease and move us closer to effective treatments.” Laura M. Cox, Ph.D., is an assistant professor in the Department of Neurology at the Ann Romney Center for Neurologic Diseases at Harvard Medical School and Brigham and Women’s Hospital. Her lab is currently investigating the role of the microbiome in neurologic diseases, including Alzheimer’s disease, Parkinson’s disease, multiple sclerosis and amyotrophic lateral sclerosis. Dr. Cox established her lab in the fall of 2021 and is identifying age-related changes in the gut microbiota that may affect Alzheimer’s disease by modulating peripheral and central immunity. Alison Goate, D. Phil., is the Jean C. and James W. Crystal Professor and Chair of the Department of Genetics and Genomic Sciences at the Icahn School of Medicine at Mount Sinai. She has worked on the genetics of neurodegenerative diseases since 1987. Over the last three decades, Dr. Goate has been part of many gene-finding teams that have successfully identified disease-causing variants for both Alzheimer’s disease and frontotemporal dementia. Teresa Gomez-Isla, M.D., is a professor of neurology at Harvard Medical School, chief of the Memory Division in the Neurology Department at Massachusetts General Hospital, associate director and clinical core leader of the Massachusetts Alzheimer’s Disease Research Center and director of the MGH Clinical Fellowship in Dementia Program. Her current research focuses on the study of brain changes associated with aging, especially those that occur very early on in Alzheimer’s disease; on understanding mechanisms of brain resilience to Alzheimer’s pathology; and on the validation of novel imaging biomarkers for early disease detection and intervention. Costantino Iadecola, M.D., is the director and chair of the Feil Family Brain & Mind Research Institute and the Anne Parrish Titzell Professor of Neurology at Weill Cornell Medical College. Considered a pioneer in establishing the concept of neurovascular unit, his research focuses on the basic mechanisms of neurovascular function and on the cellular and molecular alterations underlying ischemic brain injury, neurodegeneration and other conditions associated with cognitive impairment. Leonard Petrucelli, Ph.D., is the Ralph B. and Ruth K. Abrams Professor and Chair of the Department of Neuroscience at Mayo Clinic in Florida, and serves as vice chair for the Florida Alzheimer’s Disease Research Grant Advisory Board, chief scientific adviser for Target ALS and on the Scientific Advisory Board for Science Translational Medicine. His laboratory has been at the forefront of research investigating the cellular mechanisms that cause neurodegeneration in diseases characterized by abnormal protein aggregation like Alzheimer’s disease. Andrew S. Yoo, Ph.D., is a professor in the Department of Developmental Biology at Washington University School of Medicine in St. Louis. He has a longstanding interest in understanding genetic pathways that specify cell fates during development, and currently studies the role of microRNAs in regulating the activity of chromatin remodeling complexes during neural development and conversion of nonneuronal cells into neurons. Cure Alzheimer’s Fund is a nonprofit dedicated to funding the most promising research to prevent, slow or reverse Alzheimer’s disease. Since its founding in 2004, Cure Alzheimer’s Fund has provided 918 grants to more than 300 of the world’s leading researchers and contributed more than $219 million to research. Its funded initiatives have been responsible for many key breakthroughs in understanding the causes and pathology of Alzheimer’s disease. Cure Alzheimer’s Fund has achieved a 100% perfect score and a Four-Star rating for 13 consecutive years from Charity Navigator. Cure Alzheimer’s Fund also received a Platinum Seal of Transparency from Candid, formerly known as GuideStar. Our Board of Directors, Trustees and a core group of other donors direct their donations to our overhead expenses so that 100% of general donations go to our research program. For more information, visit CureAlz.org. Contact Details Barbara Chambers +1 978-417-9890 BChambers@CureAlz.org Company Website https://curealz.org

January 14, 2025 06:00 AM Eastern Standard Time

Cognition Therapeutics Is Targeting A Critical Form Of Dementia

Benzinga

By Johnny Rice, Benzinga Lisa Ricciardi, president and CEO of Cognition Therapeutics (NASDAQ: CGTX) was recently a guest on Benzinga’s All-Access. Cognition Therapeutics is a neuroscience company that is developing oral medications to treat neurodegenerative disorders, with recent breakthroughs in the treatment of dementia with Lewy bodies (DLB) and Alzheimer’s. The company says its drug candidate, CT1812, showed very promising results from its recently completed phase 2 trial. The drug will now progress to phase 3. Watch the full interview here: Featured photo by Rod Long on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

January 13, 2025 08:30 AM Eastern Standard Time

Video Image

Health Care Select Sector SPDR Fund (XLV): Capturing the Growth in Healthcare Consumer Spending

Select Sector SPDR

In the face of rising consumer spending on healthcare, the Health Care Select Sector SPDR Fund ( XLV ) positions itself as a strategic investment vehicle, offering investors a focused approach to the U.S. healthcare sector. Tracking healthcare stocks within the S&P 500 Index, XLV provides broad exposure to key companies leading various sub-sectors such as pharmaceuticals, health insurance, medical devices, and diagnostics. Healthcare Sector Fund: An Overview The healthcare sector continues to benefit from significant growth drivers. These include an increase in chronic diseases, an aging population, and rapid technological advancements. As the sector integrates deeper into the economic landscape, its relevance to consumers and investors alike has solidified, offering a potential opportunity for investment. Highlighting XLV's Holdings The Health Care Select Sector SPDR Fund (XLV) is characterized by its broad holdings, providing a balanced exposure to the healthcare industry. Key holdings* in the fund include: Eli Lilly (LLY) - 12.10% UnitedHealth Group (UNH) - 9.26% Johnson & Johnson (JNJ) - 6.93% AbbVie (ABBV) - 6.25% Merck (MRK) - 5.01% Thermo Fisher Scientific (TMO) - 3.96% Abbott Labs (ABT) - 3.90% Intuitive Surgical (ISRG) - 3.70% Pfizer (PFE) - 2.99% Danaher (DHR) - 2.94% These companies represent a wide spectrum of healthcare, ensuring many industries within the sector are represented. Strategic Appeal of XLV For investors seeking a comprehensive strategy to engage with the healthcare sector, XLV offers a robust solution. By spreading investments across a variety of leading healthcare companies, XLV reduces the risks associated with investing in individual stocks. This approach provides investors with a stable pathway to participate in one of the fastest-growing sectors of the economy. The fund's focus on core healthcare leaders aligns with the ongoing shifts in healthcare delivery models and consumer needs, making it an attractive option for both seasoned investors and newcomers seeking to capitalize on healthcare's growth. As healthcare continues to play an integral role in the global economy, the Health Care Select Sector SPDR Fund (XLV) stands as a practical choice for investors looking to effectively capture the steady increase in consumer spending on healthcare. With its focused holdings and strategic exposure to key industry players, XLV offers a balanced and informed approach to investing in the healthcare sector. For more information on the Health Care Select Sector SPDR Fund (XLV) please visit www.sectorspdrs.com. DISCLAIMER: This is a work of research and should not be taken as investment or financial advice. Therefore, Select Sector SPDRs or the publisher is not liable for any decision made based on the publication. About the Company: Select Sector SPDR ETFs offer flexibility and customization opportunities. Many investors have similar outlooks, but no two are exactly alike. Select Sector SPDR ETFs let investors select the sectors that best meet their investment goals. *Holdings, Weightings & Assets as of 12/31/24 subject to change DISCLOSURES The S&P 500 Index is an unmanaged index of 500 common stocks that is generally considered representative of the U.S. stock market. The index is heavily weighted toward stocks with large market capitalizations and represents approximately two-thirds of the total market value of all domestic common stocks. The S&P 500 Index figures do not reflect any fees, expenses or taxes. An investor should consider investment objectives, risks, fees and expenses before investing. One may not invest directly in an index. Transparent ETFs provide daily disclosure of portfolio holdings and weightings All ETFs are subject to risk, including loss of principal. Sector ETF products are also subject to sector risk and nondiversification risk, which generally will result in greater price fluctuations than the overall market. Diversification does not eliminate risk. An investor should consider investment objectives, risks, charges and expenses carefully before investing. To obtain a prospectus, which contains this and other information, call 1-866-SECTOR-ETF (732-8673) or visit www.sectorspdrs.com. Read the prospectus carefully before investing. ALPS Portfolio Solutions Distributor, Inc., a registered broker-dealer, is distributor for the Select Sector SPDR Trust. Media Contact: Company: Select Sector SPDRs Contact: Dan Dolan* Address: 1290 Broadway, Suite 1000, Denver, CO 80203 Country: United States Email: dan.dolan@sectorspdrs.com Website: https://www.sectorspdrs.com/ *Dan Dolan is a Registered Representative of ALPS Portfolio Solutions Distributor, Inc. ALPS Portfolio Solutions Distributor, Inc., a registered broker-dealer, is the distributor for the Select Sector SPDR Trust. SEL008109 EXP 3/31/25 Contact Details Dan Dolan +1 203-935-8103 dan.dolan@sectorspdrs.com Company Website https://www.sectorspdrs.com/

January 13, 2025 05:00 AM Eastern Standard Time

U.S. Court of Appeals Decision Marks Another Win for CoorsTek in Trademark Litigation

CoorsTek

CoorsTek Bioceramics has secured a decisive win in the U.S. Court of Appeals for the Federal Circuit affirming the company’s right to market and sell its Permallon® Tru* ceramic hip components in the U.S. The recent decision confirms the 2022 U.S. PTO Trademark Trial and Appeal Board (TTAB) cancellation of trademark registrations by Ceramtec GmbH. “Alternative sourcing of these components is necessary to prevent supply shortages for this critical care market,” said Jonathan Coors, CEO of CoorsTek. “The U.S. Court of Appeals decision marks another victory for CoorsTek in this case, but it is ultimately patients across the globe who will benefit.” CoorsTek Bioceramics entered the hip arthroplasty industry in 2013 with its Permallon® Tru technical ceramic material which contains a chromium oxide additive for improved performance, including increased hardness. The pink coloring of products manufactured from Permallon® Tru ceramic is a natural byproduct of the additive. CoorsTek initiated proceedings in 2014 following attempts by Ceramtec to enforce its trademark and trade dress claims to the color pink for its ceramic hip components. In 2022 the TTAB ruled to cancel the trademark registrations, finding the pink color is functional and a natural result of following the teachings in the expired Ceramtec patent on the material. The recent U.S. Court of Appeals decision affirms the cancellation. The 2022 TTAB decision followed a prior CoorsTek victory in the U.S. District Court for the District of Colorado, which was vacated on procedural grounds. Lucian Strong, President, CoorsTek Bioceramics said, “Products manufactured from Permallon® Tru ceramic material demonstrate exceptional mechanical performance and durability. We are pleased to continue offering these products to leading medical device OEMs who have come to rely upon high-performance, high-quality components provided by CoorsTek.” Hip systems incorporating Permallon® Tru hip components been registered for use by customers of CoorsTek Bioceramics in multiple locations across the globe, including the U.S., Korea, China, and the EU. *Formerly marketed as CeraSurf®-p About CoorsTek Bioceramics CoorsTek Bioceramics is dedicated to leading edge manufacturing of technical ceramic implantcomponents for the medical device industry. A wholly owned subsidiary of CoorsTek, Inc.,CoorsTek Bioceramics is backed by over 100 years of technical ceramics expertise. With afocus on ceramic bearing surfaces for total joint arthroplasty, CoorsTek Bioceramics components can also be found in implant devices for neurological, cardiological, spinal, andradiological applications. Since 2005, over six million CoorsTek Bioceramics components havebeen sold and distributed for clinical use. About CoorsTek Founded in 1910, CoorsTek is a leading global manufacturer of technical ceramics. By leveraging expertise in engineering and materials science, CoorsTek provides solutions to complex technical challenges in the semiconductor, medical, automotive, aerospace and other industries. With over 400 proprietary material formulations, vertically integrated systems, and unparalleled process capabilities, CoorsTek partners with its customers to make the world measurably better. Visit www.coorstek.com Contact Details CoorsTek Megan Maguire +1 303-503-2287 mmaguire@coorstek.com Company Website https://www.coorstek.com

January 09, 2025 06:00 AM Mountain Standard Time

1 ... 3 4 5 6 7 ... 256